NCT07284563

Brief Summary

The goal of this clinical trial is to evaluate an investigational ultralow dose positron emission tomography (PET imaging) technique for increased bone turnover that is found in diseases such as cancer, trauma, infection, arthritis, and other benign diseases of bone detection and monitoring. The main question it aims to answer is: Can the investigators optimize the timing, scan duration, and image reconstruction to reduce the radiation dose 10-100 fold of the current clinical standard? Participants will be injected with a radioactive tracer called Fluorine-18 (18F)-sodium fluoride (NaF) and be imaged on a new type of high sensitivity PET scanner for up to 3 hours.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
200

participants targeted

Target at P75+ for phase_2

Timeline
51mo left

Started Sep 2025

Longer than P75 for phase_2

Geographic Reach
1 country

2 active sites

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress13%
Sep 2025Jun 2030

Study Start

First participant enrolled

September 1, 2025

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

December 8, 2025

Completed
8 days until next milestone

First Posted

Study publicly available on registry

December 16, 2025

Completed
4.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 30, 2030

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 30, 2030

Last Updated

December 16, 2025

Status Verified

December 1, 2025

Enrollment Period

4.8 years

First QC Date

December 8, 2025

Last Update Submit

December 8, 2025

Conditions

Keywords

PETPET/CTlow dosenuclear imagingsodium fluoridebone

Outcome Measures

Primary Outcomes (7)

  • Signal-to-Noise Ratio (SNR)

    Measurement of signal-to-noise ratio for image quality assessment across different scan durations, reconstruction techniques, and AI-enhanced image reconstructions. Unit of Measure: SNR (unitless, numeric ratio)

    Evaluated annually (once per year), based on pooled images acquired during the preceding 12-month period.

  • Contrast-to-Noise Ratio (CNR)

    Measurement of contrast-to-noise ratio for image quality assessment across different scan durations, reconstruction techniques, and AI-enhanced image reconstructions. Unit of Measure: CNR (unitless, numeric ratio)

    Evaluated annually (once per year), based on pooled images acquired during the preceding 12-month period.

  • Coefficient of Variation (COV)

    Measurement of the coefficient of variation in selected regions for evaluating image consistency across different scan durations, reconstruction techniques, and AI-enhanced image reconstructions. Unit of Measure: Percentage (%)

    Evaluated annually (once per year), based on pooled images acquired during the preceding 12-month period.

  • Spatial Resolution (Full Width at Half Maximum - FWHM)

    Assessment of spatial resolution using full width at half maximum (FWHM) across different scan durations, reconstruction techniques, and AI-enhanced image reconstructions. Unit of Measure: Millimeters (mm)

    Evaluated annually (once per year), based on pooled images acquired during the preceding 12-month period.

  • Target-to-Background Ratio (TBR)

    Assessment of target-to-background ratio for evaluating PSMA-expressing tissue contrast across different scan durations, reconstruction techniques, and AI-enhanced image reconstructions. Unit of Measure: Ratio (unitless numeric ratio)

    Evaluated annually (once per year), based on pooled images acquired during the preceding 12-month period.

  • Qualitative Image Quality Score (Likert Scale)

    Independent qualitative evaluation of overall image quality, lesion detectability, image noise, and artifacts by nuclear medicine physicians, assessed using a 5-point Likert scale. Unit of Measure: Score on Likert Scale (1-5; 1 = worst, 5 = best)

    Evaluated annually (once per year), based on pooled images acquired during the preceding 12-month period.

  • Inter-reader Agreement (Weighted Kappa Statistics)

    Measurement of agreement among readers evaluating qualitative image quality scores, analyzed using weighted kappa statistics. Unit of Measure: Weighted kappa statistic (numeric value ranging from 0 to 1, 0 = no agreement, 1 = perfect agreement)

    Evaluated annually (once per year), based on pooled images acquired during the preceding 12-month period.

Study Arms (1)

ultralow dose 18F-NaF imaging group

OTHER

Participants will be enrolled for an ultralow dose PET scan to evaluate image quality and optimize timing and reconstruction after reducing radiation doses 10-100 fold. Participants will be injected with a very small amount of radiotracer and imaged on a PET scanner for up to 3 hours

Drug: 18F-NaF

Interventions

Participants will be injected with 18F-NaF and imaged for up to 3 hours on a PET scanner

Also known as: CT scan, PET scan, blood collection
ultralow dose 18F-NaF imaging group

Eligibility Criteria

Age18 Years - 120 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age ≥18 years.
  • Ability to provide informed consent and comply with study procedures.
  • For female participants: Must not be pregnant or breastfeeding; Negative pregnancy test required for women of childbearing potential.

You may not qualify if:

  • Participants who have exceeded NRC regulation for annual radiation exposure from prior research-related scans, including this study (50 millisievert \[mSv\] total).
  • More than four prior enrollments in this study.
  • Participants with severe claustrophobia, chronic pain, or musculoskeletal conditions that prevent completion of the PET scan
  • Concurrent treatments that may interfere with radiotracer uptake as determined by the Principle Investigator.
  • Pregnant or breastfeeding individuals (negative pregnancy test required)
  • Inability to provide informed consent
  • Any condition that, in the investigator's judgment, may compromise participant safety or study integrity.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Nuclear Imaging Institute

Englewood, New Jersey, 07631, United States

RECRUITING

Nuclear Imaging Institute

Englewood, New Jersey, 07631, United States

ENROLLING BY INVITATION

MeSH Terms

Conditions

Arthritis

Interventions

Magnetic Resonance SpectroscopyBlood Specimen Collection

Condition Hierarchy (Ancestors)

Joint DiseasesMusculoskeletal Diseases

Intervention Hierarchy (Ancestors)

Spectrum AnalysisChemistry Techniques, AnalyticalInvestigative TechniquesSpecimen HandlingClinical Laboratory TechniquesDiagnostic Techniques and ProceduresDiagnosisPuncturesSurgical Procedures, Operative

Central Study Contacts

Barbara Blanchfield

CONTACT

Study Design

Study Type
interventional
Phase
phase 2
Allocation
NA
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
SINGLE GROUP
Model Details: This is a prospective, open-label, single-center imaging study designed to evaluate the optimal timing and reconstruction parameters for ultralow dose 18F-NaF imaging using a long axial field-of-view (LAFOV) PET scanner. The study aims to determine whether normal and diseased tissue can be accurately visualized at significantly lower radiotracer doses, while optimizing scan duration and reconstruction methods to maintain diagnostic performance. A total of 200 participants will be enrolled in a single cohort, including healthy volunteers and individuals with suspected or confirmed increased bone turnover that is found in diseases such as cancer, trauma, infection, arthritis, and other benign diseases of bone. The inclusion of both healthy and diseased subjects allows for a comprehensive evaluation of normal organ uptake patterns, which is the primary objective of the study. Participants will undergo a single PET scan session per an enrollment, and be eligible for re-enrollment after 6 m
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Executive Director

Study Record Dates

First Submitted

December 8, 2025

First Posted

December 16, 2025

Study Start

September 1, 2025

Primary Completion (Estimated)

June 30, 2030

Study Completion (Estimated)

June 30, 2030

Last Updated

December 16, 2025

Record last verified: 2025-12

Locations